Akomolafe Toyin O, Okafor Emeka Emmanuel, Baruwa Sikiru, Ubuane Osimhen, Alagbile Michael, Ukaga Delafrida, Nwankwo Ijeoma, Diallo Rodio
Population Council, Abuja, Nigeria.
Society for Family Health, Abuja, Nigeria.
BMC Womens Health. 2025 Aug 21;25(Suppl 1):398. doi: 10.1186/s12905-025-03945-3.
The self-administration of the subcutaneous depot medroxyprogesterone acetate (DMPA-SC) has the potential to empower women and improve contraceptive use. Several studies have demonstrated the acceptability of the provider-administered DMPA-SC, for private, public, or community-based health providers, but less is known about self-injection training from community pharmacists (CPs) and Patent and Proprietary medicine Vendors (PPMVs) (also known as drug shops). The purpose of this study was to examine the factors associated with the acceptance of DMPA-SC self-injection training when provided by trained CPs and PPMVs in Lagos and Kaduna states.
A cross-sectional study was conducted among 186 women of reproductive age (18-49 years) who received self-injection training on DMPA-SC from trained CPs and PPMVs between August and September 2019, and between May 2022 and June 2023. Women who selected DMPA-SC, opted for self-injection, and were trained by a CP or a PPMV were invited to participate in the study. Quantitative telephone interviews were conducted with eligible clients within six (6) weeks of obtaining DMPA-SC commodities for self-injection from a trained CP or PPMV. Bivariate chi-square test and multivariate logistic regression were used to examine factors associated with acceptability and continued self-injection of DMPA-SC at home. The results were considered significant at a p value < 0.05.
More than half of the women had used a contraceptive in the past (55%), and 73% received information on DMPA-SC from a CP or PPMV. Using a family planning method prior to visiting the provider (Odds ratio (OR) = 4.31; 95% Confidence Intervals (CIs): 1.05, 17.69; p = 0.04), receiving information on DMPA-SC from friends/relative (OR = 5.08; 95% CI: 1.01, 25.62; p = 0.05), perceived high-quality care (OR = 7.72; 95% CI: 2.52, 23.61; p = 0.00) and middle-quality care (OR = 3.35; 95% CI: 1.16, 9.69; p = 0.03) were significantly associated with the likelihood of continued DMPA-SC self-injection at home. A high level of acceptance of training in DMPA-SC self-injection was significantly associated with service from PPMVs (OR = 4.94; 95% CI = 1.46, 16.75; p = 0.01) and perceived high-quality care (OR = 4.23; 95% CI = 1.62, 11.05; p = 0.00).
The results are promising for expanding DMPA-SC self-injection service delivery in Nigeria through increased method choice, and empowered users. The provision of counseling and DMPA-SC self-injection training by CPs and PPMVs is acceptable among women in Lagos and Kaduna states.
皮下注射醋酸甲羟孕酮长效避孕针(DMPA-SC)的自我给药有可能增强女性权能并改善避孕药具的使用。多项研究表明,对于私立、公立或社区卫生服务提供者而言,由提供者给药的DMPA-SC是可接受的,但对于社区药剂师(CPs)和专利及成药销售商(PPMVs,也称为药店)提供的自我注射培训了解较少。本研究的目的是调查在拉各斯州和卡杜纳州,由经过培训的CPs和PPMVs提供DMPA-SC自我注射培训时,与接受培训相关的因素。
对186名育龄妇女(18 - 49岁)进行了一项横断面研究,这些妇女在2019年8月至9月以及2022年5月至2023年6月期间接受了来自经过培训的CPs和PPMVs的DMPA-SC自我注射培训。选择DMPA-SC、选择自我注射并由CP或PPMV培训的妇女被邀请参加研究。在从经过培训 的CP或PPMV处获得用于自我注射的DMPA-SC商品后的六(6)周内,对符合条件的客户进行了定量电话访谈。使用双变量卡方检验和多变量逻辑回归来研究与在家中接受DMPA-SC自我注射的可接受性和持续自我注射相关的因素。结果在p值<0.05时被认为具有统计学意义。
超过一半的妇女过去使用过避孕药具(55%),73%的妇女从CP或PPMV处获得了关于DMPA-SC的信息。在拜访提供者之前使用计划生育方法(比值比(OR)=4.31;95%置信区间(CIs):1.05,17.69;p = 0.04)、从朋友/亲戚处获得关于DMPA-SC的信息(OR = 5.08;95% CI:1.01,25.62;p = 0.05)、感知到高质量护理(OR = 7.72;95% CI:2.52,23.61;p = 0.00)和中等质量护理(OR = 3.35;95% CI:1.16,9.69;p = 0.03)与在家中持续自我注射DMPA-SC的可能性显著相关。对DMPA-SC自我注射培训的高度接受与PPMVs提供的服务(OR = 4.94;95% CI = 1.46,16.75;p = 0.01)和感知到高质量护理(OR = 4.23;95% CI = 1.62,11.05;p = 0.00)显著相关。
这些结果对于通过增加方法选择和增强使用者权能在尼日利亚扩大DMPA-SC自我注射服务提供而言很有前景。CPs和PPMVs提供咨询和DMPA-SC自我注射培训在拉各斯州和卡杜纳州的妇女中是可接受的。